An optimized chemical synthesis of human relaxin-2

被引:12
|
作者
Barlos, Kostas K. [2 ]
Gatos, Dimitrios [2 ]
Vasileiou, Zoe [2 ]
Barlos, Kleomenis [1 ,2 ]
机构
[1] CBL Patras, Patras Ind Area, Patras, Greece
[2] Univ Patras, Dept Chem, Rion, Greece
关键词
chain combination; relaxin; solid-phase synthesis; 2-chlorotrityl resin; SOLID-PHASE SYNTHESIS; PROTECTED PEPTIDE-FRAGMENTS; BIOLOGICAL-ACTIVITY; HORMONE; MEMBER; CDNA; IDENTIFICATION; COMBINATION; PHYSIOLOGY; EXPRESSION;
D O I
10.1002/psc.1221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human gene 2 relaxin (RLX) is a member of the insulin superfamily and is a multi-functional factor playing a vital role in pregnancy, aging, fibrosis, cardioprotection, vasodilation, inflammation, and angiogenesis. RLX is currently applied in clinical trials to cure among others acute heart failure, fibrosis, and preeclampsia. The synthesis of RLX by chemical methods is difficult because of the insolubility of its B-chain and the required laborious and low yielding site-directed combination of its A (RLXA) and B (RLXB) chains. We report here that oxidation of the Met(25) residue of RLXB improves its solubility, allowing its effective solid-phase synthesis and application in random interchain combination reactions with RLXA. Linear Met(O)(25)-RLX B-chain (RLXBO) reacts with a mixture of isomers of bicyclic A-chain (bcRLXA) giving exclusively the native interchain combination. Applying this method Met(O)(25)-RLX (RLXO) was obtained in 62% yield and was easily converted to RLX in 78% yield, by reduction with ammonium iodide. Copyright (C) 2010 European Peptide Society and John Wiley & Sons, Ltd.
引用
收藏
页码:200 / 211
页数:12
相关论文
共 50 条
  • [1] Chemical Synthesis of Human Relaxin-2
    Chen, Lin
    Dalhitski, Aksana
    Fleming, Michael
    Hamilton, Andy
    Liu, Patrick
    Mastriona, Jill
    Nicholas, Gill
    Nuiry, Ilena
    Vieth, Jim
    Withers, Greg
    BIOPOLYMERS, 2013, 100 (03) : 313 - 313
  • [2] Human Relaxin-2: Design, Synthesis and Development of Novel Antagonists
    Nair, V. B.
    Samuel, C. S.
    Separovic, F.
    Wade, J. D.
    Hossain, M. A.
    BIOPOLYMERS, 2013, 100 (03) : 284 - 284
  • [3] Commercial immunoassays for human relaxin-2
    Stewart, Dennis R.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2019, 487 : 94 - 97
  • [4] The Minimal Active Structure of Human Relaxin-2
    Hossain, Mohammed Akhter
    Rosengren, K. Johan
    Samuel, Chrishan S.
    Shabanpoor, Fazel
    Chan, Linda J.
    Bathgate, Ross A. D.
    Wade, John D.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (43) : 37555 - 37565
  • [5] Role of relaxin-2 in human primary osteosarcoma
    Ma, Jinfeng
    Niu, Min
    Yang, Wenjiu
    Zang, Lina
    Xi, Yongming
    CANCER CELL INTERNATIONAL, 2013, 13
  • [6] Role of relaxin-2 in human primary osteosarcoma
    Jinfeng Ma
    Min Niu
    Wenjiu Yang
    Lina Zang
    Yongming Xi
    Cancer Cell International, 13
  • [7] Human Relaxin-2 Fusion for the Treatment of Heart Failure
    Hao, Weidong
    Garcia, Andrew
    Muniz-Medina, Vanessa
    Sadowska, Agnieszka
    Chen, Ruoyan
    Paterson, Judy
    Papworth, Monika
    Lin, Jia
    Xu, Linda
    Kuruvilla, Denison
    Pao, Diana
    Karathanasis, Sotirios
    Gao, Changshou
    Rosenthal, Kim
    Rickert, Keith
    Wilson, Susan
    Osbourn, Jane
    Walker, Jill
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2018, 124 : 115 - 115
  • [8] Autoregulation of human relaxin-2 critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter
    Dschietzig, T.
    Bartsch, C.
    Baumann, G.
    Stangl, K.
    EUROPEAN HEART JOURNAL, 2009, 30 : 220 - 220
  • [9] Autoregulation of human relaxin-2 gene expression critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter
    Dschietzig, Thomas
    Bartsch, Cornelia
    Wessler, Silja
    Baumann, Gert
    Stangl, Karl
    REGULATORY PEPTIDES, 2009, 155 (1-3) : 163 - 173
  • [10] Autoregulation of human relaxin-2 critically involves relaxin, glucocorticoid receptor and stat5 binding to glucocorticoid response half-sites in the relaxin-2 promoter
    Dschietzig, T.
    Bartsch, C.
    Baumann, G.
    Stangl, K.
    EUROPEAN HEART JOURNAL, 2011, 32 : 39 - 39